Analysts have been eager to weigh in on the Healthcare sector with new ratings on Endo International (ENDP) and Opiant Pharmaceuticals Inc (OPNT).
Endo International (ENDP)
Cantor Fitzgerald analyst Louise Chen maintained a Hold rating on Endo International today and set a price target of $18. The company’s shares opened today at $8.01.
Chen commented:
“. Despite a 1Q19 beat, we maintain our Neutral rating and 12-month PT of $18 on ENDP shares. We are on the sidelines given our concerns regarding: 1) The potential liability from opioid litigation, 2) generic drug pricing, and 3) the market opportunity for CCH. We think it will take time for ENDP to move past these overhangs. We would be more positive on ENDP’s stock if new launches, growth of existing products and pipeline advancements exceed expectations.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 7.4% and a 40.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on Endo International is a Moderate Buy with an average price target of $13.36, implying a 66.9% upside from current levels. In a report issued on April 29, Piper Jaffray also maintained a Hold rating on the stock with a $11 price target.
See today’s analyst top recommended stocks >>
Opiant Pharmaceuticals Inc (OPNT)
In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Opiant Pharmaceuticals Inc, with a price target of $38. The company’s shares opened today at $11.26, close to its 52-week low of $10.58.
Folkes observed:
“. Post 1Q19, we reiterate our Overweight rating and 12-month price target of $38. Opiant is developing treatments focused on multiple addictions, including a potential longer-lasting product for opioid overdose. The company’s ability to successfully develop products targeting addiction and overdose has been validated by the approval of Narcan nasal spray in 2015. The company entered into an agreement with Adapt Pharma (NC) to commercialize Narcan, and Opiant receives royalties on any intranasal naloxone commercialized by EBS (OW).”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.9% and a 33.7% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Collegium Pharmaceutical, and ANI Pharmaceuticals Inc.
Opiant Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
